Trials / Not Yet Recruiting
Not Yet RecruitingNCT06066216
Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer
Efficacy and Safety of Cadonilimab (AK104) Plus Chemotherapy in the Treatment of Recurrent or Advanced Endometrial Cancer: a Multicenter, Prospective Phase II Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Fujian Cancer Hospital · Other Government
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with chemotherapy in patients with recurrent or advanced endometrial cancer. The primary objective is to evaluate objective response rate of cadonilimab plus chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cadonilimab | Injectable solution |
| DRUG | Carboplatin | Injectable solution |
| DRUG | Cisplatin | Injectable solution |
| DRUG | Paclitaxel | Injectable solutionS |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2025-10-31
- Completion
- 2026-10-31
- First posted
- 2023-10-04
- Last updated
- 2024-01-23
Source: ClinicalTrials.gov record NCT06066216. Inclusion in this directory is not an endorsement.